about
The use of imaging for electrophysiological and devices procedures: a report from the first European Heart Rhythm Association Policy Conference, jointly organized with the European Association of Cardiovascular Imaging (EACVI), the Council of CardioAtrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation.Influence of time between last myocardial infarction and prophylactic implantable defibrillator implant on device detections and therapies. "Routine Practice" data from the SEARCH MI registry.Assessing the outcomes of implantable cardioverter defibrillator treatment in a real world setting: results from hospital record dataSwitching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy.Cardiac device therapy in patients with left ventricular dysfunction and heart failure: 'real-world' data on long-term outcomes (mortality, hospitalizations, days alive and out of hospital).Primary prevention of sudden cardiac death: can we afford the cost of cardioverter-defibrillators? Data from the Search-MI Registry-Italian sub-study.A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prActual pacemaker longevity: the benefit of stimulation by automatic capture verification.Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment.Long-term follow-up of patients with syncope evaluated by head-up tilt test.Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia.2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm AssociHolter ECG for pacemaker/defibrillator carriers: what is its role in the era of remote monitoring?Ventricular antitachycardia pacing therapy in patients with heart failure implanted with a cardiac resynchronization therapy defibrillator device: Efficacy, safety, and impact on mortality.Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy.Implantable electrical devices for prevention of sudden cardiac death: data on implant rates from a 'real world' regional registry.Excimer laser lead extraction by femoral approach.Impact of mitral regurgitation on the outcome of patients treated with CRT-D: data from the InSync ICD Italian Registry.Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial.QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study.New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association.Current clinical perspectives on implantable devices for atrial defibrillation.A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.Cost-effectiveness of implantable cardioverter-defibrillator in today's world.Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trialFrom lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction.Rate control in atrial fibrillation: choice of treatment and assessment of efficacy.108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands.Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs.Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.Cardiac resynchronization by pacing: an electrical treatment of heart failure.Pharmacological cardioversion of atrial fibrillation: current management and treatment options.The empowerment of translational research: lessons from laminopathies.Telecardiology and remote monitoring of implanted electrical devices: the potential for fresh clinical care perspectivesOptimization of pacing algorithms to prevent and treat supraventricular tachyarrhythmias.Cardiac resynchronization therapy in clinical practice: need for electrical, mechanical, clinical and logistic synchronization.How, why, and when may atrial defibrillation find a specific role in implantable devices? A clinical viewpoint.Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death.Cardiac resynchronization therapy during rest and exercise: comparison of two optimization methods.
P50
Q26861465-0AECE4AD-F3EB-4764-849A-CB4C44ED4DCAQ30250269-F34D9DA0-F3D6-42D4-944B-909A30F94A73Q30564158-57F99CC2-EF8A-4A9E-B780-69641F33FCF6Q30599499-47D1BE68-AAD3-4539-B868-EF942CB81BADQ30978981-78ECEE7A-52AA-449F-A118-355DD5AA1EA7Q31072272-40A9CF50-788A-4E28-B920-96101201FEB3Q31085557-46F28106-3842-4596-8540-40B0A9ACDFB6Q33157547-BD7A515B-7510-48B4-915A-5A9E8BE7DCECQ33158478-6ADD6D0F-40E0-47DF-B63C-993012758BD8Q33158584-F18AD2B0-5834-47E8-B2DF-1D04815B73F0Q33158822-33491D2A-A77A-4271-8EF8-E73076A8AB84Q33159168-F444CB41-FACB-420B-967A-73899E129CE6Q33162947-C524C282-37F0-4C63-A682-846EB661463EQ33165765-119665E0-4938-45CA-A9C5-A589B7ABD83FQ33166358-13171D1A-A125-44B5-8887-A330CEBF18BEQ33167286-A5FD657B-A02D-4653-8B28-5764AC2105C2Q33618696-57E8F93D-1AAC-4481-B084-87B37A387AC9Q33782505-B624EB24-8606-425C-A675-0D859B7133C7Q34088474-44B43C45-B0DF-4688-9489-CA5215409FA7Q34175991-60C3E7D1-D8B9-4653-8DCC-F84C01C61498Q34228805-BED4E928-50FD-4C7C-84AA-D76686D35A5DQ34387086-1DA54462-8F5C-4528-8C5D-27678B2131E3Q34493628-E1127431-91CA-4FFF-809E-808B62F4A2DCQ34521934-B8D86B17-E330-4225-BE03-119EDF93B022Q34541813-D22DE3B9-4252-4C5A-8771-6431DA1E13ECQ34626361-8E2635BB-A1FE-4E61-BC24-0307F049DE80Q34877611-636E80C1-00F5-4D9F-A5B7-8C40AAA5CEE1Q35166383-0379992F-10AE-4DD8-B04C-95291FC36F1FQ35192308-EB346B4A-B64F-4D2E-B9F7-347F331FC65CQ35201110-7627C367-7650-41CF-AB64-2322BF78E376Q35609742-FA6ACAB6-5738-42C5-8515-35D3D9420E68Q35749587-D5A07D42-DD8B-4B74-966E-77785CEB4E94Q35962527-07D5B3C5-5003-47F3-9F0B-DA11271947BEQ36281672-388EBF0B-8DE5-4F1C-B3D4-5F652A06CF4AQ36293555-3854BD86-4EAF-44D5-AC4E-2FA929C36C02Q36684059-A4D39BB6-693A-43E5-857C-2044265111E1Q36745486-DC7EF162-4D94-4938-A425-2DE78C492E71Q36762559-1D87BA67-AE23-44E4-9653-36A9C52DED7AQ36802605-8BF2EFAB-6E6E-4675-A19C-574C62BDE4E9Q36907094-2449AC6E-F305-408A-9E5F-DB701A478895
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Boriani
@ast
Giuseppe Boriani
@en
Giuseppe Boriani
@es
Giuseppe Boriani
@nl
type
label
Giuseppe Boriani
@ast
Giuseppe Boriani
@en
Giuseppe Boriani
@es
Giuseppe Boriani
@nl
prefLabel
Giuseppe Boriani
@ast
Giuseppe Boriani
@en
Giuseppe Boriani
@es
Giuseppe Boriani
@nl
P214
P244
P106
P1153
7007079613
P21
P214
P244
n2009185193
P31
P496
0000-0002-9820-4815
P735
P7859
lccn-n2009185193